Arrakis, Roche team up on RNA-targeting drugs in $190M deal

This post was originally published on this site

The partners will pursue targets across all three of Roche’s major therapeutic buckets: cancer; immunology and infectious diseases; and neuroscience, ophthalmology and rare diseases. (Arrakis Therapeutics). Share Facebook Twitter LinkedIn Email Print.

Click here to read full article